[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.191.72. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 382
Citations 0
Correction
March 18, 2019

Error in Discussion Section

JAMA Neurol. 2019;76(5):625-626. doi:10.1001/jamaneurol.2019.0475

In the Original Investigation titled “Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial,”1 published online February 7, 2019, there was an error in the Discussion section. The second-to-last sentence before the Limitations section should read: “Myocardial infarction and stroke are very costly, so the balance of NNTs for beneficial outcomes and numbers needed to harm for adverse outcomes would suggest cost utility for pioglitazone, but we have not yet conducted a cost-utility calculation.” This article was corrected online.

×